AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. UNCY
  4. [8-K] Unicycive Therapeutics, Inc. Reports Material Event

[8-K] Unicycive Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Unicycive Therapeutics reported that it has issued a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update. The company furnished that press release as Exhibit 99.1 to its Form 8-K and clarified the disclosure is being furnished, not filed for purposes of the Exchange Act and will not be incorporated by reference into registration statements, except as expressly stated. The Form 8-K also identifies the company as an emerging growth company.

Unicycive Therapeutics ha comunicato di aver pubblicato un comunicato stampa con i risultati finanziari relativi ai tre mesi chiusi il 30 giugno 2025 e di aver fornito un aggiornamento sull'attivit脿. La societ脿 ha allegato tale comunicato come Exhibit 99.1 al proprio Modulo 8鈥慘 e ha precisato che la comunicazione 猫 fornita, non depositata ai fini dell'Exchange Act e non sar脿 incorporata per riferimento nelle dichiarazioni di registrazione, salvo diversa indicazione espressa. Il Modulo 8鈥慘 indica inoltre che la societ脿 猫 una emerging growth company.
Unicycive Therapeutics inform贸 que ha emitido un comunicado de prensa con los resultados financieros correspondientes a los tres meses terminados el 30 de junio de 2025 y que proporcion贸 una actualizaci贸n comercial. La compa帽铆a adjunt贸 ese comunicado como Exhibit 99.1 a su Formulario 8鈥慘 y aclar贸 que la divulgaci贸n se est谩 proporcionando, no presentando a efectos del Exchange Act y no se incorporar谩 por referencia en las declaraciones de registro, salvo que se indique expresamente lo contrario. El Formulario 8鈥慘 tambi茅n identifica a la compa帽铆a como una emerging growth company.
Unicycive Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅橂姅 3臧滌洈 霃欖晥鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍憸頃橁碃 靷梾 順勴櫓 鞐呺嵃鞚错姼毳� 鞝滉车頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 頃措嫻 氤措弰鞛愲毳� 鞛愳偓鞚� Form 8鈥慘鞐� Exhibit 99.1搿� 鞝滌稖(鞝滉车)頄堨溂氅�, 鞚� 瓿奠嫓電� Exchange Act 氇╈爜靸� 鞝滉车霅� 瓴冹澊氅�, 鞝滌稖霅� 瓴冹澊 鞎勲媹雼�(furnished, not filed)瓿� 氇呿檿頌� 頃橁碃, 氇呾嫓鞝侅溂搿� 雼Μ 歆�鞝曤悳 瓴届毎毳� 鞝滌櫢頃橁碃 霌彪 氇呾劯靹滌棎 彀胳“搿� 韱淀暕霅橃 鞎婌潉 瓴冹澊霛缄碃 氚濏様鞀惦媹雼�. 霕愴暅 Form 8鈥慘電� 須岇偓毳� emerging growth company搿� 響滉赴頃橁碃 鞛堨姷雼堧嫟.
Unicycive Therapeutics a annonc茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour les trois mois clos le 30 juin 2025 et avoir fourni une mise 脿 jour op茅rationnelle. La soci茅t茅 a remis ce communiqu茅 en tant que Exhibit 99.1 脿 son formulaire 8鈥慘 et a pr茅cis茅 que la communication est fournie, non d茅pos茅e aux fins de l'Exchange Act et ne sera pas int茅gr茅e par renvoi aux d茅clarations d'enregistrement, sauf indication expresse contraire. Le formulaire 8鈥慘 identifie 茅galement la soci茅t茅 comme une emerging growth company.
Unicycive Therapeutics meldete, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r die drei Monate zum 30. Juni 2025 ver枚ffentlicht und ein Gesch盲ftsupdate bereitgestellt hat. Das Unternehmen hat diese Pressemitteilung als Exhibit 99.1 zu seinem Form 8鈥慘 vorgelegt und klargestellt, dass die Offenlegung im Sinne des Exchange Act bereitgestellt, nicht eingereicht wird und nicht durch Verweis in Registrierungsunterlagen aufgenommen wird, sofern nicht ausdr眉cklich anders angegeben. Das Form 8鈥慘 weist das Unternehmen au脽erdem als emerging growth company aus.
Positive
  • None.
Negative
  • None.

Insights

TL;DR: The filing furnishes Q2 results and a business update but contains no financial figures; investors must review the press release for details.

The Form 8-K notifies the market that a press release covering results for the quarter ended June 30, 2025 has been furnished as Exhibit 99.1. The filing explicitly states the press release is furnished rather than filed, which limits incorporation and liability under Section 18. Because the 8-K itself does not include revenue, earnings, guidance, or balance sheet figures, the filing alone provides limited quantitative insight; material financial details will be found only in the referenced press release.

TL;DR: This is a routine Form 8-K furnishing of a press release; the company follows standard disclosure form and notes emerging growth company status.

The document follows standard disclosure practice by furnishing a press release as Exhibit 99.1 and affirming it is not "filed" for Section 18 purposes. The filing also indicates the registrant checked the box identifying itself as an emerging growth company. The Form 8-K does not show any change in officers, material transactions, or governance actions within its text, and contains no financial tables within the filing itself.

Unicycive Therapeutics ha comunicato di aver pubblicato un comunicato stampa con i risultati finanziari relativi ai tre mesi chiusi il 30 giugno 2025 e di aver fornito un aggiornamento sull'attivit脿. La societ脿 ha allegato tale comunicato come Exhibit 99.1 al proprio Modulo 8鈥慘 e ha precisato che la comunicazione 猫 fornita, non depositata ai fini dell'Exchange Act e non sar脿 incorporata per riferimento nelle dichiarazioni di registrazione, salvo diversa indicazione espressa. Il Modulo 8鈥慘 indica inoltre che la societ脿 猫 una emerging growth company.
Unicycive Therapeutics inform贸 que ha emitido un comunicado de prensa con los resultados financieros correspondientes a los tres meses terminados el 30 de junio de 2025 y que proporcion贸 una actualizaci贸n comercial. La compa帽铆a adjunt贸 ese comunicado como Exhibit 99.1 a su Formulario 8鈥慘 y aclar贸 que la divulgaci贸n se est谩 proporcionando, no presentando a efectos del Exchange Act y no se incorporar谩 por referencia en las declaraciones de registro, salvo que se indique expresamente lo contrario. El Formulario 8鈥慘 tambi茅n identifica a la compa帽铆a como una emerging growth company.
Unicycive Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅橂姅 3臧滌洈 霃欖晥鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍憸頃橁碃 靷梾 順勴櫓 鞐呺嵃鞚错姼毳� 鞝滉车頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 頃措嫻 氤措弰鞛愲毳� 鞛愳偓鞚� Form 8鈥慘鞐� Exhibit 99.1搿� 鞝滌稖(鞝滉车)頄堨溂氅�, 鞚� 瓿奠嫓電� Exchange Act 氇╈爜靸� 鞝滉车霅� 瓴冹澊氅�, 鞝滌稖霅� 瓴冹澊 鞎勲媹雼�(furnished, not filed)瓿� 氇呿檿頌� 頃橁碃, 氇呾嫓鞝侅溂搿� 雼Μ 歆�鞝曤悳 瓴届毎毳� 鞝滌櫢頃橁碃 霌彪 氇呾劯靹滌棎 彀胳“搿� 韱淀暕霅橃 鞎婌潉 瓴冹澊霛缄碃 氚濏様鞀惦媹雼�. 霕愴暅 Form 8鈥慘電� 須岇偓毳� emerging growth company搿� 響滉赴頃橁碃 鞛堨姷雼堧嫟.
Unicycive Therapeutics a annonc茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour les trois mois clos le 30 juin 2025 et avoir fourni une mise 脿 jour op茅rationnelle. La soci茅t茅 a remis ce communiqu茅 en tant que Exhibit 99.1 脿 son formulaire 8鈥慘 et a pr茅cis茅 que la communication est fournie, non d茅pos茅e aux fins de l'Exchange Act et ne sera pas int茅gr茅e par renvoi aux d茅clarations d'enregistrement, sauf indication expresse contraire. Le formulaire 8鈥慘 identifie 茅galement la soci茅t茅 comme une emerging growth company.
Unicycive Therapeutics meldete, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r die drei Monate zum 30. Juni 2025 ver枚ffentlicht und ein Gesch盲ftsupdate bereitgestellt hat. Das Unternehmen hat diese Pressemitteilung als Exhibit 99.1 zu seinem Form 8鈥慘 vorgelegt und klargestellt, dass die Offenlegung im Sinne des Exchange Act bereitgestellt, nicht eingereicht wird und nicht durch Verweis in Registrierungsunterlagen aufgenommen wird, sofern nicht ausdr眉cklich anders angegeben. Das Form 8鈥慘 weist das Unternehmen au脽erdem als emerging growth company aus.
false 0001766140 0001766140 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 14, 2025

 

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40582   81-3638692
(State or other jurisdiction of   (Commission File Number)   IRS Employer
incorporation or organization)       Identification No.)

 

4300 El Camino AG真人官方, Suite 210

Los Alto, CA 94022

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (650) 351-4495

 

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:    Trading Symbol(s)    Name of each exchange on which registered: 
Common Stock    UNCY    Nasdaq Capital Market 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Conditions.

 

On August 14, 2025, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

99.1   Press Release of Unicycive Therapeutics, Inc. dated August 14, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 14, 2025

 

    UNICYCIVE THERAPEUTICS, INC.
   
  By: /s/ Shalabh Gupta
    Shalabh Gupta
    Chief Executive Officer

 

 

2

 

Source:

FAQ

What did Unicycive (UNCY) disclose in this Form 8-K?

The Form 8-K states that Unicycive furnished a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update; the press release is Exhibit 99.1.

Is the press release in the Form 8-K filed or furnished?

The filing explicitly says the information, including Exhibit 99.1, is being furnished and shall not be deemed 'filed' for purposes of Section 18 of the Exchange Act.

Does the Form 8-K include financial figures for Q2 2025?

No. The Form 8-K notes a press release announcing results was furnished, but the 8-K text does not include financial tables or specific results.

Where can I find the actual financial results mentioned in the filing?

The filing indicates the financial results and business update are contained in the press release furnished as Exhibit 99.1 to the Form 8-K.

Does the Form 8-K indicate any other material transactions or officer changes?

No. The Form 8-K only references the furnished press release and lists exhibits; it does not disclose material transactions or changes in officers within the filing text.
Stock UNCY logo
Unicycive Therapeutics Inc

NASDAQ:UNCY

UNCY Rankings

#5207 Ranked by Market Cap
N/A Ranked by Dividends

UNCY Latest News

Aug 14, 2025
Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Jul 24, 2025
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
Jul 8, 2025
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jul 7, 2025
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Jun 30, 2025
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

UNCY Latest SEC Filings

Aug 14, 2025
[10-Q] Unicycive Therapeutics, Inc. Quarterly Earnings Report
Aug 12, 2025
[SCHEDULE 13G/A] Unicycive Therapeutics, Inc. SEC Filing
Jul 30, 2025
[Form 4] Unicycive Therapeutics, Inc. Insider Trading Activity
Jul 30, 2025
[Form 4] Unicycive Therapeutics, Inc. Insider Trading Activity
Jul 30, 2025
[Form 4] Unicycive Therapeutics, Inc. Insider Trading Activity

UNCY Stock Data

51.20M
11.43M
4.93%
49.59%
11.13%
Biotechnology
Pharmaceutical Preparations
United States
LOS ALTOS